{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.004","statisticalMethod":"t-test, 2 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.36","value":"3.7"},{"groupId":"OG001","spread":"19.31","value":"-8.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"Change from baseline in EuroQol Visual Analogue Scale. For the ripretinib arm the minimum and maximum for the outcome were -43 to 91; the placebo arm had a range of -68 to 23. The higher value represents a higher quality of life in disease-related symptoms.","dispersionType":"Standard Deviation","groups":[{"description":"Ripretinib (150 mg) once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib).","id":"OG000","title":"Ripretinib"},{"description":"Placebo once daily in 28-day cycles until disease progression by Independent Radiologic Review (IRR) in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior therapies (therapies must include treatment with imatinib, sunitinib, and regorafenib).","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From the date of randomization (Baseline) to Cycle 2 Day 1 (Month 2)","title":"Quality of Life & Disease-Related Symptoms - EuroQol Visual Analogue Scale","type":"SECONDARY","unitOfMeasure":"Units on a Scale"}